Anti-Cancer Lapatinib Powder CAS 231277-92-2

Anti-Cancer Lapatinib powder, a chemical, has a molecular formula of C29H26ClFN4O4S and a molecular weight of 581.05800. Solubility in water is 0.007 mg/ml, and solubility in 0.1N HCl is 0.001 mg/ml at 25 C. Lapatinib is an anti-tumor drug, and it is an oral reversible small-molecule tyrosine kinase inhibitor against HER-1/ HER-2. It is mainly used in combination with capecitabine to treat ErbB-2 over-expression. In the past, it has been treated with anthracycline, taxol, trastuzumab (TCB)

Lapatinib is different from the approved humanized monoclonal antibody drug Herceptin in its mechanism of action, and it can down-regulate the cell proliferation signal by double blocking the HER-1/ HER-2 pathway.

What is Lapatinib?

Anti-Cancer Lapatinib powder, a new targeted therapy drug for breast cancer developed by GlaxoSmithKline, UK, is a tyrosine kinase inhibitor, which can effectively inhibit the tyrosine kinase activities of human epidermal growth factor receptor -1 and human epidermal growth factor receptor -2. It is unique in that it can play a role in many ways, so that breast cancer cells cannot receive the signals needed for growth. Molecular targeted therapy for breast cancer refers to the treatment of oncogenes and their related expression products related to the occurrence and development of breast cancer. Molecularly targeted drugs can inhibit or kill tumor cells by blocking the signal transduction of tumor cells or related cells to control the changes in cell gene expression. On March 14th, 2007, the US Food and Drug Administration approved the combination of lapatinib and capecitabine to treat patients with advanced or metastatic breast cancer who were over-expressed by ErbB2 and treated with anthracycline, paclitaxel, and trastuzumab.

How does lapatinib work?

Anti-Cancer Lapatinib powder combined with capecitabine is suitable for HER2 patients with advanced or metastatic breast cancer who have received anthracycline, paclitaxel, and trastuzumab in the past. Note: It must be used by patients with recurrence and metastasis who have progressed after receiving trastuzumab treatment. There is no data to support its use in people outside this indication.

In vitro, lapatinib can inhibit CYP3A4 and CYP2C8 at therapeutic concentration, and it is mainly metabolized by CYP3A4. Drugs that inhibit this enzyme activity can significantly increase the blood concentration of lapatinib. Lapatinib is the transport ground of P- glycoprotein and drugs that inhibit glycoprotein may increase its blood concentration.

What are the adverse reactions to using lapatinib?

1. More than 10% of the adverse reactions observed in clinical trials are mainly gastrointestinal reactions, including nausea, diarrhea, stomatitis, indigestion, dry skin, rash, back pain, dyspnea, and insomnia.

2. When combined with capecitabine, adverse reactions include nausea, diarrhea, vomiting, poor palmoplantar touch, etc. Individual patients may have decreased left ventricular ejection fraction and interstitial pneumonia.

3. The most common side effects are gastrointestinal side effects, namely nausea, vomiting, diarrhea, and other symptoms, as well as skin redness, itching, pain, and fatigue. There are also rare but serious side effects, including heart and lung.

4. When the patient's frequency of left ventricular beats above the second grade decreases, it must be stopped to avoid heart failure. When LVEF returns to normal or the patient is asymptomatic, the drug can be used again at a lower dose two weeks later.

5. Because lapatinib is a drug metabolized by the CYP enzyme system in the liver, we must pay attention to the dose adjustment when using other drugs that can induce or inhibit CYP enzyme. Generally, pregnant women should not use lapatinib, because its pregnancy toxicity is classified as D. Therefore, it is not recommended for pregnant women or pregnant women unless there is no absolute need or great benefit to the mother.

How to choose more products

Send your Inquiry for more details, Click email：allen@faithfulbio.com Now.

You can also contact me via WhatsApp：+86 13137770562

A variety of shipping methods for you to choose

Disclaimer: The articles published on this site are mainly used to promote academic exchanges and learning, and do not mean that this site agrees with its views or confirms the authenticity of its contents. Please filter carefully. If you believe this article is infringing, please contact the administrator. We are not responsible for the consequences of using the information and services on this website.

Note: This compound should be used for research purposes only. These claims have not been evaluated by the Food and Drug Administration. Please consult your doctor and learn about available studies before using them. This product is not intended to diagnose, treat, cure or prevent any disease.

Hot Tags: anti-cancer lapatinib powder cas 231277-92-2, China, suppliers, manufacturers, factory, customized, wholesale, buy, price, bulk, pure, producer, discount, for sale, in stock, free sample, raw powder, raw material, made in China